Standard BioTools (LAB) Provides Preliminary Fourth Quarter 2022 Revenue and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update
January 9, 2023 8:30 AM ESTContinued commercial and strategic execution delivers sequential core revenue growth of 4%9% to $26 million$27 million in Q4 2022 for full year total of approximately $94 million$95 million
Business restructuring and SBS program on track to deliver over 20% reduction in operating expenses or more than $30 million and reduces annual operating expenses to approximately $100 million exiting Q4. GAAP operating expense reductions are expected to be over 25% and over $35 million.
On track for achieving stated goal of 65%68% non-GAAP gross margins by the end of 2023. GAAP... More
